Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
公司网站 :
http://www.evelobio.com
总经理:Craig R. Jalbert
建立时间:2014
公司总部:Cambridge
领域:Health technology
行业:Pharmaceuticals: major